The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
GEN1286 looks dead, though MCLA-129 continues for now.
And the company says it won’t need to carry out another trial.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
A fresh licensing deal tidies up years of work between the two companies.
And that could affect the drug's third-line accelerated approval.
